What is the current market price of Ensartinib per box?

Ensartinib is a targeted drug developed by China's domestic pharmaceutical company Beida Pharmaceuticals. It is mainly used to treat patients with ALK positive non-small cell lung cancer (NSCLC). As a domestic innovative drug, ensartinib has gradually gained recognition from clinicians and patients due to its good efficacy and relatively low price. Betta Pharmaceuticals is committed to promoting the widespread application of this drug in China and improving patient accessibility.

At present, ensartinib has been officially launched in the Chinese market, and patients can purchase it through regular hospitals and pharmacies. As a domestic drug, the price of ensartinib has certain advantages over similar imported drugs. The price of a single box is about more than 1,000 yuan. The reasonable price allows more patients to afford the relevant treatment costs, especially when it is not fully covered by medical insurance, and the financial burden is relatively controllable.

Although ensartinib is already on the market, the specific price may vary depending on region, hospital procurement policy and medical insurance coverage. Some regions have begun to include ensartinib in the scope of medical insurance reimbursement, further reducing patients' treatment costs. Before taking medication, patients are advised to consult local hospital pharmacies and medical insurance policies in detail to obtain accurate price information and reimbursement support.

In general, ensartinib, as a domestic targeted drug, is becoming an important treatment option for patients with ALK positive non-small cell lung cancer due to its good efficacy and relatively affordable price. With the continuous development of domestic innovative drugs and the improvement of medical insurance policies, the market coverage of ensartinib is expected to further increase in the future, helping more patients obtain better treatment effects.

Reference materials:https://www.drugs.com/